

Imetelstat



Included Products: Rytelo (imetelstat)

Created: 09/12/2024

Revised: 09/12/2024

Reviewed: 09/12/2024

Updated: 10/01/2024

All Diagnoses

Initial Criteria: All Diagnoses		If yes	If no
1.	Is the drug prescribed by or in consultation with a hematologist?	Continue to #2	Do not approve.
2.	Did the provider provide serum EPO labs, history of ESA use, and evidence of low-intermediate risk disease as defined by NCCN?	Continue to #3	Continue to #3
3.	Does the member have serum EPO level > 500 mU/mL?	Continue to #4	Do not approve.
4.	Has the member failed at least 8 weeks of Epoetin Alfa or 12 weeks of darbepoetin?	Continue to #5	Do not approve.
5.	Has the member failed, or have a contraindication to, Reblozyl?	Continue to #6	Do not approve.
6.	Approve for 2 months.		
Renewal Criteria		If yes	If no
1.	Is there documentation which demonstrates a decrease in number of transfusions compared to baseline?	Continue to #2	Do not approve.
2.	Approve for 6 months.		